Only One Week After Voiding Two Years of Tests, Theranos Now Faces Consumer Class Action Lawsuit
Retired Gilead (GILD) Exec Returns as His Replacement Exits
Sarepta (SRPT) Rockets After the FDA Delays Ruling on DMD Drug
BioPharm Executive: Election 2016: It Does Not Look Good for Biotech
Sophiris Bio (SPHS) Slashes Workforce in Half as Firm Explores Strategic Options
Count Celgene (CELG) and Gilead (GILD) as New Suitors to Acquire the Popular Medivation (MDVN)
Serial BioPharma Entrepreneurial Team Launches Arrivo BioVentures with $49 Million
Amid Restructuring and Lawsuits, Novartis AG (NVS) Indicates It Might Sell $14 Billion Roche (RHHBY) Stock Without a Premium
Pfizer (PFE)'s Quest to Become a Cancer Powerhouse
Sanofi (SNY) Formally Files Papers to Oust the Medivation (MDVN) Board that Rejected Its $9.3 Billion Bid
FDA Panel Unanimously Backs Novo Nordisk A/S (NVO)'s Diabetes Combo Drug Ideglira
Innocoll (INNL)'s Painkiller Passes Final Phase III Tests, Heads for 2017 Launch
PDL BioPharma (PDLI) Bags Novartis AG (NVS)'s Hypertension Drugs Via $107 Million Investment in Noden Pharma
Iceni Launches as New Company
Ariad (ARIA) Names Former Bristol-Myers Squibb (BMY) Exec as Chief Commercial Officer
Nine Bay Area Biotechs Vie to be the “Next Genentech (RHHBY)”
Novartis AG (NVS) CEO Attempts to Rebuild as Seven Execs Jump Ship in the Space of Five Months
Novartis AG (NVS) Trial Stopped Early on Positive Data, Gets Ready to Take on Pfizer (PFE)'s Ibrance
See All News >
See All News >